{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:27:34Z","timestamp":1790645254995,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clbc.2025.10.017","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T16:02:51Z","timestamp":1762012971000},"page":"208-222.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunohistochemical Changes After Neoadjuvant Chemotherapy and Their Impact on Breast Cancer Survival: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1996-7428","authenticated-orcid":false,"given":"Marcelo","family":"Antonini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5973-623X","authenticated-orcid":false,"given":"Andr\u00e9","family":"Mattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1418-0295","authenticated-orcid":false,"given":"Gil","family":"Facina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-2890","authenticated-orcid":false,"given":"Francisco Pimentel","family":"Cavalcante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1643-727X","authenticated-orcid":false,"given":"Felipe","family":"Zerwes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0589-1423","authenticated-orcid":false,"given":"Fabricio Palermo","family":"Brenelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-6898","authenticated-orcid":false,"given":"Ant\u00f4nio Luis","family":"Frasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2113-6324","authenticated-orcid":false,"given":"Eduardo Camargo","family":"Millen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4816-8366","authenticated-orcid":false,"given":"Rodrigo Caires","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2247-5800","authenticated-orcid":false,"given":"Let\u00edcia Xavier","family":"F\u00e9lix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5657-7419","authenticated-orcid":false,"given":"Juliana Calado","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7516-0215","authenticated-orcid":false,"given":"Marina Di\u00f3genes","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-3067","authenticated-orcid":false,"given":"Marcelo","family":"Madeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-8719","authenticated-orcid":false,"given":"Rog\u00e9rio","family":"Fenile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3789-4461","authenticated-orcid":false,"given":"Henrique Lima","family":"Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-6114","authenticated-orcid":false,"given":"Leonardo Ribeiro","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-8598","authenticated-orcid":false,"given":"Ruffo de Freitas","family":"Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6216-6327","authenticated-orcid":false,"given":"Renata","family":"Arakelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1211-2823","authenticated-orcid":false,"given":"Renata Montarroyos","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2161-818X","authenticated-orcid":false,"given":"Vitoria Rassi Mahamed","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9941-9191","authenticated-orcid":false,"given":"Luiz Henrique","family":"Gebrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clbc.2025.10.017_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1130","key":"10.1016\/j.clbc.2025.10.017_bib0002","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20211033","article-title":"Understanding breast cancer as a global health concern","volume":"95","author":"Wilkinson","year":"2022","journal-title":"Br J Radiol"},{"key":"10.1016\/j.clbc.2025.10.017_bib0003","article-title":"Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2025.10.017_bib0004","doi-asserted-by":"crossref","first-page":"65","DOI":"10.21037\/cco-24-54","article-title":"Real-world evidence of survival outcomes in breast cancer subtypes after neoadjuvant chemotherapy in a Brazilian reference center","volume":"13","author":"Antonini","year":"2024","journal-title":"Chin Clin Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2025.10.017_bib0005","first-page":"107","article-title":"De-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer patients","volume":"51","author":"Franceschini","year":"2024","journal-title":"CEOG"},{"key":"10.1016\/j.clbc.2025.10.017_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.984587","article-title":"Surgical options of the breast and clinical outcomes of breast cancer patients after neoadjuvant chemotherapy: a single-center retrospective study","volume":"12","author":"Sang","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2025.10.017_bib0007","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5306\/wjco.v5.i3.382","article-title":"Significance of immunohistochemistry in breast cancer","volume":"5","author":"Zaha","year":"2014","journal-title":"World J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.10.017_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64492-9","article-title":"Does immunohistochemical marker conversion affect the prognosis in breast cancer patients receiving neoadjuvant chemotherapy?","volume":"14","author":"Uzun","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.clbc.2025.10.017_bib0009","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3390\/medicina60050737","article-title":"Impact of neoadjuvant chemotherapy (NAC) on biomarker expression in breast cancer","volume":"60","author":"Lee","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.clbc.2025.10.017_bib0010","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1186\/s12885-020-07179-4","article-title":"Effect of neoadjuvant therapy on breast cancer biomarker profile","volume":"20","author":"Rey-Vargas","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2025.10.017_bib0011","article-title":"HER2 and hormone receptor conversion after neoadjuvant therapy for breast cancer","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.10.017_bib0012","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13000-024-01451-y","article-title":"Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients","volume":"19","author":"Wang","year":"2024","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.clbc.2025.10.017_bib0013","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"issue":"3","key":"10.1016\/j.clbc.2025.10.017_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247802","article-title":"Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: results from a tertiary Cancer Center in Saudi Arabia","volume":"16","author":"Al-Saleh","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2025.10.017_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104417","article-title":"Disparities in access to anti-HER2 therapies in neoadjuvant chemotherapy: a prognostic analysis based on real-world data comparing Brazil's public and private healthcare systems","volume":"80","author":"Antonini","year":"2025","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.clbc.2025.10.017_bib0016","first-page":"45","article-title":"Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and ki-67 in patients with breast cancer","volume":"20","author":"Avci","year":"2015","journal-title":"J buon"},{"key":"10.1016\/j.clbc.2025.10.017_bib0017","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.3332\/ecancer.2021.1162","article-title":"Impact of immunohistochemical profile changes following neoadjuvant therapy in the treatment of breast cancer","volume":"15","author":"Cand\u00e1s","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.clbc.2025.10.017_bib0018","first-page":"381","article-title":"Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER\/PR status act as better prognosticators?","volume":"7","author":"Chatterjee","year":"2015","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"9","key":"10.1016\/j.clbc.2025.10.017_bib0019","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1245\/s10434-012-2318-2","article-title":"Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer","volume":"19","author":"Chen","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2025.10.017_bib0020","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/diagnostics11122249","article-title":"Biomarkers changes after neoadjuvant chemotherapy in breast cancer: a seven-year single institution experience","volume":"11","author":"Coiro","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"12","key":"10.1016\/j.clbc.2025.10.017_bib0021","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1245\/s10434-018-6608-1","article-title":"Impact of neoadjuvant chemotherapy on breast cancer subtype: does subtype change and, if so, how?: IHC profile and Neoadjuvant chemotherapy","volume":"25","author":"De La Cruz","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2025.10.017_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231895","article-title":"Impact on survival of estrogen receptor, progesterone receptor and ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer","volume":"15","author":"Ding","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2025.10.017_bib0023","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2016.03.006","article-title":"Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER\/PR and HER2 expression - implications for the practising oncologist","volume":"60","author":"Gahlaut","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2025.10.017_bib0024","article-title":"Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients","volume":"9","author":"He","year":"2022","journal-title":"Front Surg"},{"issue":"1","key":"10.1016\/j.clbc.2025.10.017_bib0025","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4143\/crt.2023.386","article-title":"Changes in invasive breast carcinomas after neoadjuvant chemotherapy can influence adjuvant therapeutic decisions","volume":"56","author":"Jaime Dos Santos","year":"2024","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clbc.2025.10.017_bib0026","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4143\/crt.2014.262","article-title":"Impact of molecular subtype conversion of breast cancers after neoadjuvant chemotherapy on clinical outcome","volume":"48","author":"Lim","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.clbc.2025.10.017_bib0027","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4274\/ejbh.galenos.2022.2022-1-4","article-title":"Prognostic value of receptor change after neoadjuvant chemotherapy in breast cancer patients","volume":"18","author":"\u00d6zdemir","year":"2022","journal-title":"Eur J Breast Health"},{"issue":"2","key":"10.1016\/j.clbc.2025.10.017_bib0028","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013554","article-title":"Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma","volume":"98","author":"Peng","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.clbc.2025.10.017_bib0029","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.3390\/cancers15123068","article-title":"Pre- and post-neoadjuvant clinicopathological parameters can help in the prognosis and the prediction of response in HER2+ and triple negative breast cancer","volume":"15","author":"Pons","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.clbc.2025.10.017_bib0030","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1634\/theoncologist.12-6-636","article-title":"Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy","volume":"12","author":"Tacca","year":"2007","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.clbc.2025.10.017_bib0031","first-page":"4086","article-title":"Prognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients","volume":"7","author":"Tan","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"10.1016\/j.clbc.2025.10.017_bib0032","first-page":"191","article-title":"Effect of neoadjuvant chemotherapy on the expression of hormone receptors and ki-67 in Chinese breast cancer patients: a retrospective study of 525 patients","volume":"32","author":"Wu","year":"2017","journal-title":"J Biomed Res"},{"issue":"12","key":"10.1016\/j.clbc.2025.10.017_bib0033","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.prp.2013.08.012","article-title":"Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer","volume":"209","author":"Yang","year":"2013","journal-title":"Pathol Res Pract"},{"issue":"8","key":"10.1016\/j.clbc.2025.10.017_bib0034","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jso.24762","article-title":"Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer","volume":"116","author":"Yoshida","year":"2017","journal-title":"J Surg Oncol"},{"issue":"34","key":"10.1016\/j.clbc.2025.10.017_bib0035","doi-asserted-by":"crossref","first-page":"36894","DOI":"10.18632\/oncotarget.5050","article-title":"Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.clbc.2025.10.017_bib0036","doi-asserted-by":"crossref","first-page":"e1230","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst Rev"},{"issue":"S1526\u20138209 (25)","key":"10.1016\/j.clbc.2025.10.017_bib0037","first-page":"00220","article-title":"Prognostic impact of real-world immunohistochemical changes in breast cancer treated with neoadjuvant chemotherapy","author":"Antonini","year":"2025","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2025.10.017_bib0038","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.humpath.2016.12.019","article-title":"Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?","volume":"62","author":"Xian","year":"2017","journal-title":"Hum Pathol"},{"issue":"11","key":"10.1016\/j.clbc.2025.10.017_bib0039","doi-asserted-by":"crossref","first-page":"9600","DOI":"10.18632\/oncotarget.3292","article-title":"Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study","volume":"6","author":"Jin","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.clbc.2025.10.017_bib0040","article-title":"Analyzing neoadjuvant chemotherapy effects in HER2-low breast cancer: real world data","volume":"16","author":"Antonini","year":"2024","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.clbc.2025.10.017_bib0041","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1055-9965.EPI-10-0097","article-title":"Analytic variability in immunohistochemistry biomarker studies","volume":"19","author":"Anagnostou","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.clbc.2025.10.017_bib0042","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)\/HER2(-) breast cancer: a randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.clbc.2025.10.017_bib0043","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.clbc.2025.10.017_bib0044","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamaoncol.2024.3456","article-title":"Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: a systematic review and meta-analysis","volume":"10","author":"Villacampa","year":"2024","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2025.10.017_bib0045","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JOP.777003","article-title":"American society of clinical oncology\/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"6","author":"Hammond","year":"2010","journal-title":"J Oncol Pract"},{"issue":"3","key":"10.1016\/j.clbc.2025.10.017_bib0046","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s12094-024-03661-8","article-title":"Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis","volume":"27","author":"de Moraes","year":"2025","journal-title":"Clin Transl Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925003076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925003076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:09:07Z","timestamp":1773407347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925003076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1526820925003076"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.10.017","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemical Changes After Neoadjuvant Chemotherapy and Their Impact on Breast Cancer Survival: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}